A dual-hormone drug drove even greater weight loss than its predecessors. Tirzepatide activates two gut-hormone receptors and produced dramatic results in trials. It extended a wave of metabolic medicines reshaping obesity care.
Two targets
The design is dual. The drug hits both GIP and GLP-1 receptors. Effects combine.
Large weight loss
Results were striking. Trial participants shed a substantial share of body weight. Records were set.
Metabolic benefits
Health improved. Blood sugar and other markers responded. Diabetes care benefits too.
Side effects
Trade-offs exist. Nausea and other effects are common. Tolerability varies.
Supply strain
Demand surged. Shortages followed rapid uptake. Access was uneven.
A shifting field
The paradigm moved. Obesity is treated as a chronic metabolic disease. More drugs are coming.
The bottom line
Tirzepatide activates two gut-hormone receptors and drove dramatic weight loss in trials. It improved metabolic markers amid side effects and shortages. It deepened the obesity-treatment revolution.
